Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Catalyst Pharmaceuticals Inc CPRX

Healthcare Biotechnology
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for... see more

Recent & Breaking News (NDAQ:CPRX)

Catalyst Pharmaceuticals to Hold Fourth Quarter Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 19th, 2019

GlobeNewswire March 11, 2019

Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2019

GlobeNewswire February 28, 2019

Catalyst Pharmaceuticals Announces Publication of Phase 3 Clinical Trial Data for Firdapse® for the Treatment of Lambert-Eaton Myasthenic Syndrome

GlobeNewswire February 26, 2019

Catalyst Pharmaceuticals to Present at the 21st Annual BIO CEO & Investor Conference

GlobeNewswire February 5, 2019

56 Biggest Movers From Yesterday

Benzinga.com  February 5, 2019

35 Stocks Moving In Monday's Mid-Day Session

Benzinga.com  February 4, 2019

Catalyst Pharmaceuticals Announces Publication of Clinical Data from the Investigator-Sponsored Phase IIb Study Evaluating Firdapse® for the Treatment of MuSK Antibody Positive Myasthenia Gravis

GlobeNewswire January 4, 2019

Catalyst Pharmaceuticals Announces Definitive Agreement with Endo for Vigabatrin Tablets

GlobeNewswire December 18, 2018

Report: Exploring Fundamental Drivers Behind Sabre, Catalyst Pharmaceuticals, Renewable Energy Group, Luminex, Parker Drilling, and Apollo Endosurgery — New Horizons, Emerging Trends, and Upcoming Developments

GlobeNewswire December 11, 2018

Catalyst Pharmaceuticals Announces Conference Call to Discuss Commercialization Plan for Firdapse® (amifampridine) for Lambert-Eaton Myasthenic Syndrome (LEMS)

GlobeNewswire December 3, 2018

52 Biggest Movers From Friday

Benzinga.com  December 3, 2018

48 Biggest Movers From Yesterday

Benzinga.com  November 30, 2018

The Daily Biotech Pulse: Twist In Protagonist Tale, Catalyst's Autoimmune Disorder Drug Approved

Benzinga.com  November 29, 2018

FDA Approves Firdapse® (amifampridine) for the Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS)

GlobeNewswire November 29, 2018

The Daily Biotech Pulse: IntelliPharmaCeutics Generic Antidepressant Gets FDA Nod, GW Pharma Earnings

Benzinga.com  November 28, 2018

Catalyst Pharmaceuticals Announces Firdapse® (amifampridine) New Drug Application Continues Under Review

GlobeNewswire November 27, 2018

Catalyst Pharmaceuticals Announces Third Quarter 2018 Financial Results and Provides Corporate Update

GlobeNewswire November 7, 2018

Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates

Benzinga.com  November 1, 2018

Catalyst Pharmaceuticals to Hold Third Quarter Financial Results and Corporate Update Conference Call and Webcast on Thursday, November 8th, 2018

GlobeNewswire October 31, 2018

Market Trends Toward New Normal in AllianceBernstein Holding, Five9, Simpson Manufacturing, Green Plains, Catalyst Pharmaceuticals, and Commercial Vehicle Group — Emerging Consolidated Expectations, Analyst Ratings

GlobeNewswire October 10, 2018